Hedge Fund Levin Capital Is Betting On These Stocks

In a new filing with the Securities and Exchange Commission, John Levin‘s Levin Capital Strategies disclosed a new passive stake in New Senior Investment Group Inc (NYSE:SNR), a company that went public at the beginning of November. The fund disclosed holding 3.94 million shares of the company, which represent 5.96% of the company’s outstanding common stock. In a separate filing, Levin reported slightly trimming its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) to 1.16 million shares from 1.18 million shares disclosed in its latest 13F filing; the passive stake amasses 4.9% of the company.

Bio-Rad Laboratories

New Senior Investment Group Inc (NYSE:SNR) is a real estate investment trust that has been recently spun-off from Newcastle Investment Corp. (NYSE:NCT). At the end of October shareholders received one share of New Senior Investment for every share of Newcastle. At the end of September, Levin Capital held around 5.93 million shares of Newcastle Investment Corp.

New Senior Investment Group Inc (NYSE:SNR) holds a portfolio of senior housing properties in the US. The company’s portfolio is separated into Managed Properties and Triple Net Lease Properties, which New Senior Investment Group Inc (NYSE:SNR) leases to tenants. The stock of the REIT has decreased by 10% since it began trading.

On the other hand, in Bio-Rad Laboratories, Inc. (NYSE:BIO) Levin has been a long-term shareholder. The fund first disclosed holding around 93,600 shares as of the end of June 2010, while the stock gained more than 35% since then. The company is a $3.50 billion manufacturer and supplier of products for science research, healthcare, analytical chemistry markets. So far this year Bio-Rad Laboratories, Inc. (NYSE:BIO)’s stock lost around 3% as the company reported a slight increase in financial results. Its revenue for the third quarter appreciated by 5% on the year to $531 million, while its net income surged to $0.39 per share from a loss of $0.25 per share last year.

Overall investors have mixed sentiments regarding Bio-Rad Laboratories, Inc. (NYSE:BIO), as our data show. At the end of September, 26 funds held long positions in the company, up from 22 in the previous quarter, out of a total of more than 700 funds that we track. However, the value of the total number of shares held by these funds went down by $7.48 million to $476.38 million. John W. Rogers’ Ariel Investments is the largest shareholder among funds that we track, holding 1.07 million shares of the company as of the end of September.

Disclosure: none